Hasn't faired well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Indoco Remedies Consolidated December 2022 Net Sales at Rs 399.20 crore, up 11.51% Y-o-Y

Manaksia Aluminium Company Ltd, Kothari Products Ltd, Celebrity Fashions Ltd and Khaitan Chemicals & Fertilizers Ltd are among the other losers in the BSE’s ‘B’ group today, 24 January 2023.

Indoco Remedies Ltd leads losers in ‘B’ group

Indoco Remedies tumbled 8.60% to Rs 369.95 after the company’s net profit declined 15% to Rs 27.9 crore despite an 18% rise in net revenues to Rs 410.6 crore in Q3 FY23 over Q3 FY22.

Indoco Remedies slumps after dismal Q3 performance

Indoco Remedies Ltd clocked volume of 3.36 lakh shares by 14:14 IST on NSE, a 9 times surge over two-week average daily volume of 37294 shares

Volumes soar at Indoco Remedies Ltd counter

Indoco believes that this will not have an impact on the supplies and the existing revenues from this facility

Indoco Remedies shares gain even as USFDA inspection ends with 9 observations

Net Sales are expected to increase by 18.3 percent Y-o-Y (down 2.2 percent Q-o-Q) to Rs 4,236 crore, according to Nirmal Bang.

Indoco Remedies Q3 PAT seen up 46.1% YoY to Rs 482 cr: Nirmal Bang

Indoco Remedies shares rallied more than 7 percent to Rs 415.35 and formed long bullish candle on the daily charts with strong volumes. Overall it has seen a good run up after breaking out long downward sloping resistance trend line adjoining August 12, 2021 and August 3, 2022.

Trade Spotlight | What should you do with Gujarat State Petronet, Indoco Remedies, NLC India on Friday?

GNFC is expected to be retesting a breakout of a rounding bottom formation after five years on the weekly timeframe whereas on the daily timeframe the stock is likely to be taking support from a support zone and bouncing with high volumes which can be used as a confluence towards the bullish view.

Hot Stocks | Bet on GNFC, Indoco Remedies for decent return in short term, here’s why

ICICI Direct is bullish on Indoco Remedies recommended buy rating on the stock with a target price of Rs 465 in its research report dated November 13, 2022.

Buy Indoco Remedies; target of Rs 465: ICICI Direct

Aarti Industries’ Q2 adjusted Ebitda at Rs 270 crore (up 31.5 per cent YoY) stood largely in‐line with YES Securities’ estimate. The YoY growth stemmed from adjustment for shortfall fee of Rs 52 crore in the in base quarter, it said

What analysts say on PVR, Aarti Industries, Indoco Remedies & Mishra Dhatu

The company expects Ebitda margin to reach 25% in the next three years.

Indoco Remedies Q2 Results Review - Margin Expansion Drives Earnings Growth: Systematix

Indoco Remedies Limited is engaged in the manufacture of pharmaceutical products. The Company primarily manufactures and markets Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).

Indoco Remedies Ltd